Table 1 Patient characteristics and factors associated to the use of CT in the EoL
Total No. (%) | New CT scheme prescription > 30 days to death No. (%) | New CT scheme prescription ≤30 days to death No. (%) | p-value | Last CT cycle administration > 14 days to death No. (%) | Last CT cycle administration ≤14 days to death No. (%) | p-value | |
|---|---|---|---|---|---|---|---|
Overall | 365 (100.0) | 329 (90.1) | 36 (9.8) | – | 339 (92.9) | 26 (7.1) | – |
Gender | |||||||
Male | 215 (58.9) | 190 (88.4) | 25 (11.6) | 0.18 | 200 (93.0) | 15 (7.0) | 0.90 |
Female | 150 (41.1) | 139 (92.7) | 11 (7.3) | 139 (92.7) | 11 (7.3) | ||
Age | |||||||
Median (range) | 70 (33–87) | 71 (33–87) | 63.5 (37–83) | 0.13 | 70 (33–87) | 62.5 (45–80) | 0.09 |
≤ 70 years | 188 (51.5) | 164 (87.2) | 24 (12.8) | 0.05 | 170 (90.4) | 18 (9.6) | 0.06 |
> 70 years | 177 (48.5) | 165 (93.2) | 12 (6.8) | 169 (95.5) | 8 (4.5) | ||
Period of study inclusion | |||||||
2007–2010 | 142 (38.9) | 129 (90.9) | 13 (9.1) | 0.72 | 136 (95.8) | 6 (4.2) | 0.09 |
2011–2014 | 223 (61.1) | 200 (89.7) | 23 (10.3) | 203 (91.0) | 20 (8.9) | ||
Previous treatment for advanced disease | |||||||
None | 120 (32.9) | 108 (90.0) | 12 (10.0) | 0.95 | 105 (87.5) | 15 (12.5) | < 0.01 |
At least one | 245 (67.1) | 221 (90.2) | 24 (9.8) | 234 (95.5) | 11 (4.5) | ||